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Abstract
Background: Diabetes is an important contributor to the health inequity between Aboriginal and non-Aboriginal
Australians. This study aims to estimate incidence rates of diabetes and to assess its associations with impaired
fasting glucose (IFG) and impaired glucose tolerance (IGT) among Aboriginal participants in a remote community.
Methods: Six hundred and eighty six (686) Aboriginal Australians aged 20 to 74 years free from diabetes at
baseline were followed for a median of 11 years. During the follow-up period, new diabetes cases were identified
through hospital records. Cox proportional hazards models were used to assess relationships of the incidence rates
of diabetes with IFG, IGT and body mass index (BMI).
Results: One hundred and twenty four (124) new diabetes cases were diagnosed during the follow up period.
Incidence rates increased with increasing age, from 2.2 per 1000 person-years for those younger than 25 years to
39.9 per 1000 person-years for those 45-54 years. By age of 60 years, cumulative incidence rates were 49% for
Aboriginal men and 70% for Aboriginal women. The rate ratio for developing diabetes in the presence of either
IFG or IGT at baseline was 2.2 (95% CI: 1.5, 3.3), adjusting for age, sex and BMI. Rate ratios for developing diabetes
were 2.2 (95% CI: 1.4, 3.5) for people who were overweight and 4.7 (95% CI: 3.0, 7.4) for people who were obese at
baseline, with adjustment of age, sex and the presence of IFG/IGT.
Conclusions: Diabetes incidence rates are high in Aboriginal people. The lifetime risk of developing diabetes
among Aboriginal men is one in two, and among Aboriginal women is two in three. Baseline IFG, IGT and obesity
are important predictors of diabetes.
Background
Diabetes is an important cause of coronary heart disease
[1] and renal failure in Aboriginal people [2], contribut-
ing considerably to the 17 year life expectancy gap
between Aboriginal and non-Aboriginal Australians.
The prevalence of diabetes in Aboriginal Australians is
higher than that in the general Australian population
[3]. Most of the available data have been from cross-sec-
tional studies. The incidence of diabetes in Aboriginal
people from an 8-year follow-up study has been
reported [4]. However, there are no data on age-specific
and cumulative incidence, which is important informa-
tion regarding individuals’ risks of developing diabetes
during a defined period.
Impaired glucose tolerance (IGT) and impaired fasting
glucose (IFG) have been defined by the World Health
Organisation [5]. The American Diabetes Association
(ADA) Expert Committee on the Diagnosis and Classifi-
cation of Diabetes Mellitus has recommended lowering
the diagnostic threshold of IFG from 6.1 to 5.6 mmol/L,
which supposedly results in a similar prevalence of IFG
and IGT and increases the concordance between the
two groups with respect to risk definition [6]. However,
people with IFG may have a different background risk
when compared with those with IGT[7]. Predictive
values of IFG and IGT for risk of incident diabetes in
Aboriginal people have not been investigated.
In this study we aimed to i) describe incidence rates of
diabetes in an Aboriginal cohort with a median of
11 years of follow-up; and ii) examine relations of inci-
dent diabetes with the presence of baseline IFG, IGT
and body mass index (BMI).
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In 1992 a community-wide screening program was
initiated in a remote Aboriginal community in Austra-
lia’s Northern Territory. Participants were offered a
baseline examination and testing between 1992 and
1995. Eight hundred and ninety seven (897) adults aged
20 to 74 years (representing over 80% of the adult popu-
lation in the community) were included in the program.
Baseline plasma glucose concentrations were measured
in 802 participants: 414 participants had 75 g oral glu-
cose tolerance tests (OGTT); 126 had fasting plasma
glucose tests without OGTT; and 262 had random
plasma glucose tests only. The remaining 95 participants
had no baseline plasma glucose tests and were excluded
in this analysis.
Of those 802 participants, 71 had clinically diagnosed
diabetes before the baseline examination, and 45 had a
new diagnosis of diabetes made at the baseline examina-
tion according to World Health Organisation (WHO)
1999 criteria [5]. The remaining 686 participants (321
females and 365 males) free from identifiable diabetes at
baseline were followed up to 13 years.
The project was approved by the Behavioural and
Social Science Ethical Review Committee of the Univer-
sity of Queensland.
Measurements
New diabetes cases that occurred during the follow-up
period after the baseline examination were identified
through reviewing hospital records according to ICD-9
CM code of 250 and ICD-10-AM code of E11, and out-
patient clinical records. Only the records related to the
first documented diagnosis of diabetes for each indivi-
dual were used for the analysis. All participants’ hospital
records were followed up to 30 April 2005. For those
who were diagnosed as having diabetes during the fol-
low-up period, their follow-up time was from the time
of initial screening visit to the time of having a diagnosis
first documented in hospital records. Those who had
not reached an endpoint were considered “censored” at
t h ed a t eo f3 0A p r i l2 0 0 5 .P a r t i c i p a n t sw h oh a dn o
documented diagnoses of diabetes in hospital records
and had died before the end of follow-up were censored
at the time of death.
An individual with a baseline fasting plasma glucose
concentration of 5.6 - 6.9 mmol/L was considered as hav-
ing IFG while those with a 2 hour plasma glucose (or
random glucose) of 7.8 - 11.0 mmol/L as having IGT.
Body weight and height were measured at the baseline
examination for calculation of BMI (kg/m
2). Other base-
line measurements included smoking and drinking status,
blood pressure, serum cholesterol and urine albumin
creatinine ratio (ACR). Detailed baseline data collection
methods have been reported elsewhere [3].
Statistical analysis
The data were partitioned into age bands of < 25, 25-34,
35-44, 45-54 and 55+ years. For individuals who fell
into more than two age bands during the follow-period,
their total follow-up time was subdivided and allocated
into corresponding age bands as described by Clayton
and Hills [8]. Incidence rates were estimated for each
age group using the numbers of newly diagnosed dia-
betes cases divided by the person-years of follow-up.
Cumulative incidence of diabetes was estimated using
the Kaplan-Meier product-limit method. Rate ratios and
their 95% confidence intervals were estimated using the
Cox proportional hazards model adjusting for potential
confounding factors. All analyses were performed using
Stata 10.0 [9].
Results
The baseline characteristics of the study cohort are pre-
sented in Table 1. Among 686 adults who were free
from diabetes at baseline, 101 had either IGT alone (58
participants) or IFG alone (36 participants) or both (7
participants). During the follow-up period, 124 of those
participants were diagnosed as having diabetes. Inci-
dence rates increased with increasing age, from 2.2 per
1000 person-years for those younger than 25 years to
39.9 per 1000 person-years for those 45-54 years (Table
2). However, there was a slight drop of the incidence
rate for those aged 55 years or older (30.5/person-years).
The cumulative incidence rates are shown in Table 3.
Females had a higher incidence rate than their male
counterparts. It is estimated that, by age of 60 years,
70% of women and 49% of men expect to have a diag-
nosis of diabetes.
T h ep r e s e n c eo fI F G / I G Ta tb a s e l i n ea n dB M Iv a l u e s
were important predictors of diabetes. As shown in
Table 4, the presence of either form of impaired glucose
regulation (IGT or IFG) at baseline increased the risk of
Table 1 Baseline characteristics of study participants
Female (n = 321) Male (n = 365)
Age (± SD), years 35.0 (13.5) 30.8 (10.0)
BMI (± SD), kg/m2 24.1 (6.2) 22.6 (4.4)
Waist circumference (± SD), cm 89.7 (14.8) 85.2 (12.7)
Systolic pressure (± SD), mmHg 117 (19) 125 (16)
Diastolic pressure (± SD), mmHg 71 (13) 77 (13)
Total cholesterol (± SD), mmol/L 4.3 (1.0) 4.8 (1.1)
IFG/IGT 59 (18%) 42 (12%)
BMI < 25 kg/m
2 189 (60%) 266 (73%)
25 - 29 kg/m
2 71 (22%) 77 (21%)
≥ 30 kg/m
2 58 (18%) 22 (6%)
BMI: body mass index
IFG: impaired fasting glucose
IGT: impaired glucose tolerance
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and overweight increased the risk of incident diabetes in
both normal glucose and impaired glucose regulation
groups with a dose-response relationship.
Adjusting for age, sex and BMI at baseline, the rate
ratio for developing diabetes among participants with
either baseline IFG or IGT was 2.2 (95% 1.5, 3.3) (Table
5). The rate ratios for overweight and obesity at baseline
were 2.2 (95% CI: 1.4, 3.5) and 4.7 (95% CI: 3.0, 7.4)
respectively, with adjustment of age, sex, and the pre-
sence of IGT/IFG at baseline. Even though baseline obe-
sity and impaired glucose regulation significantly
increased the risk of diabetes, a considerable proportion
of diabetes cases (35 persons or 28%) occurred from
those with normal baseline BMI (< 25 kg/m
2)a n d
plasma glucose values.
Discussion
In this study we found that the incidence of diabetes in
Aboriginal people was high, comparable to those in
other high risk populations such as Pima Indians [10]
and people in Mauritius [11]. The observed diabetes
incidence rate among participating Aboriginal adults
was higher than those reported in the general Australian
population [12] and in European [13,14] and American
black and white populations [15]. For example, diabetes
incidence rates in Aboriginal women were 4-8 times as
high as those in the general Australian women for dif-
ferent age groups, while the corresponding values in
Aboriginal men were 2-4 times of their general Austra-
lian counterparts [12].
Given the life expectancy of around 60 years for Aus-
tralian Aboriginal peoples, the cumulative incidence of
diabetes at age of 60 years calculated in this study pro-
vides an approximate estimate of lifetime risk of devel-
oping diabetes in this population. That is, the lifetime
risk of diabetes among these Aboriginal men is one in
two, and among these Aboriginal women is two in
three. A previous study reported that lifetime risk of
diabetes was 33% for males and 39% for females in the
US [16]. The high lifetime probability of diabetes among
Aboriginal Australians calls for implementation of effec-
tive primary prevention strategies at the population
level. It also calls for a more sophisticated understanding
Table 2 Incidence rates (per 1000 person-years) of
diabetes in Aboriginal people
Incidence rate (95% CI)
Age group
Years
Females Males Total
< 25 2.6 (0.4, 18.2) 2.0 (0.3, 13.9) 2.2 (0.6, 8.9)
25-34 22.1 (14.4, 33.9) 7.2 (4.0, 13.0) 12.9 (9.1, 18.2)
35-44 26.4 (17.0, 40.9) 23.0 (15.3, 34.7) 24.5 (18.2, 33.0)
45-54 53.2 (35.1, 80.8) 23.6 (11.8, 47.2) 39.9 (27.9, 57.0)
55+ 28.2 (15.2, 52.4) 34.5 (16.5, 72.4) 30.5 (19.0, 49.1)
Table 3 Estimated cumulative incidence rates (%)
Cumulative incidence rate (95% CI)
Age point Females Males
25 1.4 (0.2, 9.3) 0.9 (0.1, 6.2)
30 10.0 (5.5, 17.8) 3.0 (1.1, 7.8)
35 21.0 (14.4, 30.2) 7.9 (4.5, 13.6)
40 31.1 (23.2, 40.8) 17.6 (12.2, 25.1)
45 39.2 (3.07, 49.1) 27.9 (20.6, 37.0)
50 55.4 (46.1, 65.2) 36.6 (27.7, 47.2)
55 62.8 (53.2, 72.5) 42.4 (31.7, 55.0)
60 69.9 (60.1, 79.1) 48.6 (36.3, 62.5)
Table 4 Incidence rates (per 1000 person years) of
diabetes by baseline plasma glucose and BMI levels
Incidence rate (95% CI)
Baseline normal glucose group
Normal BMI 8.6 (6.2, 12.0)
Overweight 21.2 (14.1, 31.9)
Obesity 53.2 (36.0, 78.7)
Baseline IFG/IGT group
Normal BMI 24.6 (13.6, 44.4)
Overweight 66.9 (41.0, 109.2)
Obesity 124.7 (73.8, 210.5)
BMI: body mass index
IFG: impaired fasting glucose
IGT: impaired glucose tolerance
Table 5 Adjusted rate ratios for developing diabetes by
impaired glucose regulation and BMI levels at baseline
Group at baseline Adjusting for Rate
ratio
95%
CI
P value
Normal glucose
group
Age, sex, BMI 1.0
IFG/IGT group 2.2 1.5, 3.3 <
0.0001
Normal glucose
group
Age, sex, BMI,
IGT
1.0
IFG group 1.7 1.0, 3.0 0.02
Normal glucose
group
Age, sex, BMI,
IFG
1.0
IGT group 1.7 1.0, 2.8 0.04
Normal BMI group Age, sex, IFG, IGT 1.0
Overweight group 2.2 1.4, 3.5 0.0003
Obese group 4.7 3.0, 7.4 <
0.0001
BMI: body mass index
IFG: impaired fasting glucose
IGT: impaired glucose tolerance
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population.
Results from several longitudinal studies have shown
that the presence of IGT/IFG is a significant predictor
of the development of diabetes [11,17-19]. This study
adopted the new American Diabetes Associate threshold
for IFG. Studies in other populations have shown that
those with new threshold of IFG are at increased risk of
diabetes [7,20]. In our study, IFG and IGT identified dis-
tinct groups with 36 participants with IFG only and 58
with IGT only. Their contributions to the prediction of
incident diabetes are independent of each other, sug-
gesting that the causes and physiological bases of IFG
and IGT may be somewhat different. Raised hepatic glu-
cose output and a defect in early insulin secretion are
characteristics of IFG, while peripheral insulin resistance
is often characteristic of IGT [21]. The presence of
either IFG alone or IGT alone doubled the risk of dia-
betes compared to the normal glucose group. Even after
adjusting for the presence of either IFG or IGT, the
other remained to be a significant predictor of diabetes.
This supports investigation of both IFG and IGT to cap-
ture high risk individuals in Aboriginal populations.
Baseline BMI value is an import predictor of diabetes.
Overweight individuals have over twofold risk and obese
individuals have over fourfold risk of diabetes relative to
those with normal baseline BMI values. This finding is
consistent with that from a previous study in Aboriginal
populations [4]. BMI has been found to be a significant
predictor of diabetes in the US general population [22]
and in other high risk populations such as South African
Indians [23], Pima Indians [24] and Nauruans [25].
The dose-response relationship between BMI and risk
of diabetes exists regardless the presence of IFG/IGT.
This is comparable with the results from a study of
American Indians which have shown that BMI is a sig-
nificant predictor of diabetes in both normal glucose
t o l e r a n c eg r o u pa n dI G Tg r o u p[ 1 7 ] .W ef o u n dt h e
association between IFG/IGT and diabetes was indepen-
dent of obesity status. The IFG/IGT group had a higher
risk of diabetes in all normal weight, overweight and
o b e s eg r o u p s .O u rf i n d i n g ss t r e s st h ei m p o r t a n c eo f
reducing obesity and managing IFG and IGT on dia-
betes prevention. However, it should be pointed out that
a considerable proportion of diabetes cases were from
those with a normal baseline BMI (< 25 kg/m
2)a n d
normoglycemia, suggesting that other factors might have
been important for the development of diabetes in this
population. We previously reported that albuminuria
was an important predictor of diabetes [26]. Hematocrit
[27], inflammatory markers [28-31] and gamma-gluta-
myltransferase [32] are some potential useful predictors.
Assessing novel risk factors in this population is cur-
rently in progress.
Some limitations of this study should be pointed out.
First, the diabetes cases were identified through
reviews of hospital and outpatient records. Ninety two
percent of the participants had at least one occasion of
hospitalisations during the follow up period. We could
miss some diagnoses when diabetes was not severe
enough for hospital care. This may underestimate the
true incidence. Second, we relied on routinely docu-
mented diagnosis information in hospital records for
identification of diabetes cases during follow-ups, and
misdiagnosis might occur at routine practice. Further-
more, the true date of diagnosis of diabetes was prob-
ably earlier than that documented in hospital records.
Third, there was potential for loss to follow-up of par-
ticipants’ hospital care due to out-migration to other
communities. In reality, the hospital in our study set-
ting is the only hospital serving the entire region, so
that most people who had out-migrated to commu-
nities within several hundred kilometres, the usual pat-
tern, would still have their hospital care recorded in
the centralised hospital data system. Permanent out-
migration is very uncommon. Fourth, because the sam-
ple size was relatively small for old age groups in this
study, the incidence estimates may not be precise, as
reflected in the wide 95% confidence intervals. Fifth,
the data were collected in a remote community, it
remains to be verified if the findings apply to other
Aboriginal groups. Caution should be exercised in gen-
eralising the findings to the broader Aboriginal popula-
tion in Australia. Sixth, cumulative incidence rates
were estimated based on incidence data collected over
one decade rather than over life time. If incidence
rates change over time, so does an individual’s life
time risk of diabetes. Finally, the presence of IGT
among some participants was determined according to
the postprandial glucose values due to the absence of
oral glucose tolerance tests. Some IGT individuals
might have been misclassified as normal.
Conclusions
Diabetes incidence rates are high in Aboriginal people.
The lifetime risk of developing diabetes among Aborigi-
nal men is one in two, and among Aboriginal women is
two in three. IFG and IGT identify people who have an
increased risk of diabetes. Baseline IFG, IGT and obesity
are important predictors of diabetes.
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